Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Establishing a high-quality reputation, Jiankangyuan won important awards in the China Listed Company Reputation Ranking: “Biopharmaceutical Listed Company with the Greatest Growth Potential” and “Best Listed Company CEO”

Published Time:

2022-12-29

On December 28, the "11th China Listed Companies Summit Forum," a series of events successfully held by Daily Economic News, a mainstream financial media outlet under Chengdu Media Group, concluded. During the forum, the 2022 China Listed Companies Reputation List, which has attracted much attention from the capital market, was unveiled. With its high-quality innovative R&D in the Greater Health sector and huge growth potential, Joincare Pharmaceutical Group Industry Co., Ltd. won the "Biopharmaceutical Company with the Greatest Growth Potential" award, and Jiankangyuan Pharmaceutical Group President Yu Xiong won the "Best Listed Company CEO" award.

As a highly influential high-end financial forum in China, the China Listed Companies Summit Forum has been successfully held for eleven years. This year's forum, themed "Empowering the Real Economy and Stimulating Innovation," brought together representatives from various sectors, including leaders from national ministries and commissions, renowned economists, and heads of listed companies. This included prominent guests such as Liu Shijin, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and Vice President of the China Development Research Foundation; Tu Guangshao, CPPCC National Committee Member and Executive Director of the Shanghai Advanced Institute of Finance, Shanghai Jiao Tong University; and Wu Xiaoqiu, President of the China Capital Market Research Institute and former Vice President of Renmin University of China. They engaged in multi-faceted discussions on the future path of high-quality economic development in China, contributing their wisdom to promoting the development of the real economy and seizing development opportunities in the new journey.

According to the organizers, the central theme of this year's China Listed Companies Reputation List selection was "Shaping Characteristics, Returning Value." The selection covered the three major global capital markets: A-shares, Hong Kong stocks, and US stocks, with fierce competition among participating companies. The Reputation List was compiled through multiple rounds of screening, including online nominations, big data screening, data model screening, public voting, and expert panel reviews.

In the first stage of online nominations, a large number of investors actively nominated their favorite listed companies (and individuals), demonstrating that the Reputation List can maximally reflect the reputation of listed companies among investors, signifying that the listed companies on the list possess a high-quality, reputable brand image in the eyes of investors. It is through the votes of countless investors expressing their opinions that listed companies are put to the test by investors, allowing them to cultivate a more valuable and authentic reputation.

The year 2022, which is drawing to a close, was an extremely complex year for the A-share market and investors. For Jiankangyuan, with its tens of billions of revenue and thirty-year history, continued innovation and growth required arduous efforts. Jiankangyuan Pharmaceutical Group has always been deeply involved in the Greater Health industry, and in recent years has further consolidated its leading position in the domestic high-end inhaled formulation sector. According to publicly available information, Jiankangyuan currently has 7 varieties and 11 specifications of inhaled formulations on the market, with more than 30 respiratory products under development. It has successfully achieved coverage of all categories of asthma and COPD inhaled treatment drugs in existing and under-development products, and has rapidly opened up and covered the domestic market through opportunities such as national negotiations and centralized procurement. This year, with the launch of Jianketo, Jiankangyuan's major improved new drug tobramycin inhalation solution, Jiankangyuan President Yu Xiong stated that in recent years, the incidence and prevalence of bronchiectasis have been increasing year by year. The launch of Jianketo will change the situation where there are no available drugs in the domestic market for nebulized inhalation treatment of bronchiectasis, providing more support for patients with bronchiectasis.

Several research institutions have expressed optimism about the group's continued delivery on its R&D capabilities in the inhaled formulation field. Winning these awards is a testament to investor and capital market recognition of Jiankangyuan Group's comprehensive strength and future growth potential.

Faced with the new situation and requirements of the Greater Health industry, Jiankangyuan has persevered, upholding its vision and mission of "For Health, For Tomorrow" and "Making Good Medicines with Care," focusing on its pharmaceutical main business, and firmly implementing a dual-engine strategy of innovative drugs and high-barrier complex formulations, while maintaining stable operations. Standing at a new starting point in the future, Jiankangyuan will continue to uphold product quality and focus on R&D, forging ahead in inheritance and innovation, gradually growing into an industry-influential pharmaceutical company, and contributing to the construction of a healthy China.

 

Source: Daily Economic News